The experts on our Technical Advisory Group provide guidance and insight on potential guarantee opportunities that will positively impact healthcare markets.
Dr Andrew Hill has over 20 years of experience working in drug development and costing. He is a Senior Visiting Research Fellow in Liverpool University’s Pharmacology Department focussing on treatment access issues, particularly for HIV, viral hepatitis, TB and cancer.
Andrew has been an advisor to the World Health Organization (WHO) and the Clinton Health Access Initiative (CHIA) since 2015 providing guidance on HIV treatments and designing clinical trial programmes for antiretroviral dose optimisation. Andrew is also a Member of the WHO Fair Pricing Committee, which discusses challenges in – and solutions for – current medicine pricing systems. Previously, Andrew worked on the development of HIV antiretrovirals, and advised pharmaceutical firms on the design and analysis of clinical trials and drug development.
Andrew is the author of over 40 research papers on HIV and has been involved in the use of HIV RNA and CD4 counts in the regulatory approval of antiretrovirals, the standardisation of HIV clinical trial analyses, and several systematic reviews of HIV clinical trials. He has been on the editorial board of “AIDS” and runs a charity, “Living and Loving” which supports children with HIV/AIDS in Thailand.
Andrew Lever is Professor of Infectious Diseases (ID) at the University of Cambridge, where he is also an honorary consultant Physician. He qualified in Wales and trained in General Medicine and ID mainly in London. He did his MD funded by the Medical Research Council (MRC) on primary immunodeficiency during which he identified the risk of transmission of hepatitis through immunoglobulin concentrates. He held a Wellcome Trust funded lectureship in ID at the Royal Free Hospital where he studied the interferon system and chronic viral infections including hepatitis B and cytomegalovirus. He moved to Harvard to work on the newly emerging virus HIV and while there identified the HIV encapsidation signal.
Since then he has been an academic clinician in London and, since 1991, Cambridge, combining clinical work with a research programme on the structural and molecular biology of viruses, focussed on HIV but including other viruses such as rotavirus and dengue. He has had continuous MRC grant support since 1989 to pursue this work. He has collaborated with GSK in development of novel antiviral agents.
He continues to do clinical research and was part of the recent RIVER trial of HIV eradication and contributed to the ‘London’ HIV cure patient. He has published widely on infectious diseases on subjects including, HIV, hepatitis, meningitis and malaria.
Melissa has had a twenty-year career in global vaccines spanning the public and private sectors. She is currently consulting independently and as a Senior Advisor with MMGH Consulting with clients including Gavi, the Vaccine Alliance, the Bill and Melinda Gates Foundation, PATH, the World Health Organization, The Wellcome Trust, the Coalition for Epidemic Preparedness and Innovations and vaccine manufacturers.
From 2013 until late 2017, Melissa led the design and implementation of Gavis’ market shaping efforts. In that capacity she was accountable for ensuring adequate and timely supply of vaccines at affordable prices for Gavi, for setting long-term access strategies for sixteen vaccines and for leading Alliance relationships with the vaccine industry. During this time she was engaged in evaluating or negotiating six bespoke agreements with industry, resulting in savings of over $500 million.
Prior to Gavi, Ms. Malhame had nearly 20 years of experience in the vaccine industry with both a large multi-national manufacturer and an emerging vaccine company. Her industry experience includes leading late stage vaccine development, business and commercial development, marketing and sales. She served as a member of the Center for Global Development working group on the Future of Global Healthcare Procurement and as an advisor to Jansen Global Public Health.
Ms. Malhame has published on the experiences and results of market shaping and pricing transparency. She received a Masters in Business Administration from the Johnson Graduate School of Management at Cornell University.
Helen obtained an intercalated BSc in 1988, followed by a degree in medicine in 1991 (both University of London). In 1997, she was awarded an MRC Clinical Training Fellowship to undertake a PhD with Adrian Hill in Oxford, and was later awarded a PhD in 2001 (University of London). In 2001 she was awarded a Wellcome Clinician Scientist Fellowship, allowing her to complete her clinical training and subsequently awarded a CCST in HIV and GU Medicine in 2003. In 2005 and 2010, she was awarded a Wellcome Senior Clinical Research Fellowship. She currently holds a Wellcome Trust Investigator Award. Helen was elected to be a Fellow of the Academy of Medical Sciences in 2019.
Since 2001, Helen has led a TB vaccine research group at the University of Oxford. She led the development of MVA85A, the first new TB vaccine candidate to enter efficacy testing. Her current areas of focus include the development of controlled human mycobacterial challenge models, aerosol delivery of vaccines and immunomonitoring in clinical trials. Helen collaborates with several research groups across Africa in TB vaccine clinical trials.
Most recently, Helen has been leading the coordination of COVID-19 drug trials within Oxford and nationally and is now leading a programme to establish a controlled human infection model with SARS CoV2 which will allow the evaluation of protective immunity.
George is a healthcare professional who has worked in the pharmaceutical, in vitro diagnostics (IVD) and medical device industries for almost fifty years. He is a registered pharmacist and is currently working as a consultant to several IVD companies including Syncona, BBI and Renishaw Diagnostics, sharing his expertise in regulatory affairs, clinical trials, marketing, development and reimbursement systems, general management and acquisitions, and raising investment.
George is the Executive Chairman of Probe Scientific and on the Board of Sarissa Biomedica. Probe Scientific is developing a non-invasive blood sampling system using microdialysis. In his role at Sarissa, George examines grant applications for a range of health innovations, particularly in digital health and the use of artificial intelligence in health diagnosis in developing countries. George is also the Founder and first Chairman of the British In Vitro Diagnostics Association (BIVDA), which aims to make the UK Government aware of the role of diagnostics in primary healthcare.
George began his career as a Clinical Trials Manager and Regulatory Affairs Manager at Boehringer Ingelheim and subsequently the Unilever subsidiary Unipath. At Unipath, he supported the successful development, trialling and launch of Clearblue pregnancy and Clearplan fertility tests and was in charge of Unilever’s cancer project linking antibodies raised against tumour-associated antigens for therapy and imaging of various cancers. He then moved to Shield Diagnostics (now Axis-Shield), and was responsible for identifying partners to develop and launch new products and negotiated contracts with IVD organisations such as Abbott Laboratories, Roche, Dade Behring, BioRad, Bayer Diagnostics (now Siemens) and Beckman Coulter.